Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2025 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

roche holding ag - RHHVF

RHHVF

Close Chg Chg %
331.43 8.22 2.48%

Closed Market

339.65

+8.22 (2.48%)

Volume: 527.00

Last Updated:

Mar 28, 2025, 3:15 PM EDT

Trade Now

Company Overview: roche holding ag - RHHVF

RHHVF Key Data

Open

$336.35

 Day Range

331.90 - 339.65

52 Week Range

233.12 - 354.19

 Market Cap

N/A

Shares Outstanding

NaN

 Public Float

688.71M

Beta

N/A

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

N/A

Yield

N/A

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

4.20K

  

RHHVF Performance

1 Week
 
 -3.14%
 
1 Month
 
 3.13%
 
3 Months
 
 20.93%
 
1 Year
 
 32.59%
 
5 Years
 
 9.83%
 

RHHVF Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 26
Full Ratings ➔
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Roche Holding Ag - RHHVF

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
68.69B 66.26B 65.34B 68.69B
Sales Growth
+10.55% -3.54% -1.39% +5.13%
Cost of Goods Sold (COGS) incl D&A
21.55B 19.72B 17.60B 18.20B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
4.86B 4.00B 3.87B 3.89B
Depreciation
3.16B 3.02B 3.07B 3.05B
Amortization of Intangibles
1.70B 982.13M 796.75M 842.54M
COGS Growth
+23.69% -8.48% -10.76% +3.38%
Gross Income
47.14B 46.54B 47.74B 50.49B
Gross Income Growth
+5.42% -1.28% +2.58% +5.78%
Gross Profit Margin
+68.63% +70.23% +73.06% +73.51%
2021 2022 2023 2024 5-year trend
SG&A Expense
27.98B 27.30B 29.31B 29.52B
Research & Development
14.99B 14.71B 14.72B 14.26B
Other SG&A
12.98B 12.59B 14.59B 15.26B
SGA Growth
+9.52% -2.40% +7.35% +0.70%
Other Operating Expense
260.32M 201.03M 233.68M 275.93M
Unusual Expense
3.03B 4.59B 3.55B 7.98B
EBIT after Unusual Expense
15.88B 14.44B 14.65B 12.73B
Non Operating Income/Expense
3.53B 3.33B 1.98B 2.13B
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
372.98M 636.61M 921.38M 1.42B
Interest Expense Growth
-20.07% +70.68% +44.73% +53.80%
Gross Interest Expense
372.98M 636.61M 921.38M 1.42B
Interest Capitalized
- - - -
-
Pretax Income
19.03B 17.14B 15.70B 13.44B
Pretax Income Growth
-0.57% -9.95% -8.38% -14.39%
Pretax Margin
+27.71% +25.87% +24.03% +19.57%
Income Tax
2.69B 2.93B 1.92B 2.96B
Income Tax - Current - Domestic
2.86B 4.66B 3.15B 4.91B
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
(170.63M) (1.74B) (1.24B) (1.95B)
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
16.34B 14.17B 13.75B 10.43B
Minority Interest Expense
1.10B 1.16B 956.99M 1.03B
Net Income
15.24B 13.01B 12.79B 9.40B
Net Income Growth
+0.04% -14.64% -1.62% -26.54%
Net Margin Growth
+22.18% +19.63% +19.58% +13.68%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
15.24B 13.01B 12.79B 9.40B
Preferred Dividends
- - - -
-
Net Income Available to Common
15.24B 13.01B 12.79B 9.40B
EPS (Basic)
17.925 16.2567 16.0134 11.7924
EPS (Basic) Growth
+0.63% -9.31% -1.50% -26.36%
Basic Shares Outstanding
850.00M 800.00M 799.00M 797.00M
EPS (Diluted)
17.7153 16.2567 15.9138 11.7189
EPS (Diluted) Growth
+0.62% -8.23% -2.11% -26.36%
Diluted Shares Outstanding
860.00M 800.00M 804.00M 802.00M
EBITDA
23.77B 23.03B 22.06B 24.60B
EBITDA Growth
+0.07% -3.09% -4.23% +11.51%
EBITDA Margin
+34.60% +34.76% +33.76% +35.81%

Roche Holding Ag in the News

Inside the race for a COVID-19 treatment pill

Pfizer and its rivals, including U.S.-based Merck & Co Inc and Swiss pharmaceutical Roche Holding AG are racing to produce the first antiviral pill that people could take at early signs of the illness. Their shared goal: filling a key treatment hole by helping people recently-infected with coronavirus to avoid becoming seriously ill and needing hospitalization.